Tesamorelin is a 44-amino-acid synthetic analog of human growth-hormone-releasing hormone (GHRH), carrying a trans-3-hexenoyl modification at the N-terminus. That structural addition confers resistance to dipeptidyl peptidase-IV (DPP-IV) degradation and extends the molecule's functional half-life — characteristics that are central to its clinical-research track record. The mechanism is direct: binding to pituitary GHRH receptors triggers pulsatile GH secretion, downstream IGF-1 elevation (~50% over placebo per Falutz 2007), and selective reduction in visceral adipose tissue (VAT) of 15-18% in lipodystrophy subjects over 26 weeks.
The landmark trials — Falutz et al. 2007 (NEJM, 412 subjects), the 2010 26-week extension, Stanley et al. 2014 (JAMA, HIV-associated NAFLD showing 32% liver fat reduction), and the 12-month Stanley 2019 Lancet HIV extension — all used subcutaneous administration. What they share beyond efficacy data is a careful operational approach to where the needle goes. In the Falutz series, the abdominal SC site was the primary injection field. In the Stanley 2019 Lancet HIV trial — the longest tesamorelin study in the published literature at 12 months — investigators explicitly permitted rotating SC sites as a protocol provision. That single design choice reflects what extended peptide research consistently demonstrates: injection site is a method variable, not a footnote.
Investigators in the UAE using tesamorelin from REVIVE LAB UAE on multi-month protocols need a structured site-rotation plan. The deltoid region is the natural addition to any abdominal-dominant rotation schedule: it offers adequate SC tissue depth, consistent anatomical landmarks, and lower intersite pharmacokinetic variability than the thigh in most research-context subjects.
The deltoid muscle originates at the lateral clavicle, acromion, and scapular spine, inserting at the deltoid tuberosity of the humerus. For SC research protocols, investigators target the subcutaneous fat layer overlying the lateral deltoid, not the muscle belly itself. This distinction matters: an inadvertent intramuscular injection changes absorption kinetics, increases local reactivity, and introduces an uncontrolled variable into any quantitative protocol.
The validated lateral deltoid SC injection zone is bounded as follows:
This creates a roughly 4×4 cm safe injection square on the lateral upper arm. Within this zone, SC tissue depth varies by subject — accurate characterization before the first deltoid administration guides needle selection:
| SC Tissue Depth | Typical Context | Needle Length | Insertion Angle | Skin Pinch |
|---|---|---|---|---|
| < 8 mm | Lean / low adiposity | 4–6 mm | 45° | Required |
| 8–12 mm | Average SC layer | 6–8 mm | 45° or 90° | Optional |
| > 12 mm | Higher SC adiposity | 8 mm | 90° | Not required |
Measuring SC tissue depth via caliper pinch at the injection site before the first deltoid injection is standard practice for establishing reproducible site parameters across a multi-week protocol.
None of the four major tesamorelin trials published a head-to-head comparison of deltoid versus abdominal SC pharmacokinetics. What they do provide is a robust framework for SC administration that investigators can adapt for multi-site rotation:
| Trial | N | Dose | Admin | Primary Site | Duration |
|---|---|---|---|---|---|
| Falutz et al. 2007 (NEJM) | 412 | 2 mg/day SC | Self-admin | Abdominal | 26 weeks |
| Falutz et al. 2010 (extension) | Subset | 2 mg/day SC | Self-admin | Abdominal | +26 weeks |
| Stanley et al. 2014 (JAMA) | 50 | 2 mg/day SC | Self-admin | Abdominal | 12 weeks |
| Stanley et al. 2019 (Lancet HIV) | 61 | 2 mg/day SC | Self-admin | Rotating SC | 12 months |
The Stanley 2019 Lancet HIV extension — the longest published tesamorelin protocol — is the design precedent for multi-site rotation. A 1 mg/day research-context dose appears in sub-threshold titration designs; 2 mg/day remains the primary efficacy benchmark. Research investigators building extended UAE protocols should map their dosing calendar against both the Falutz lipodystrophy timeline (26 weeks minimum for meaningful VAT change) and the Stanley 2019 liver-fat endpoint (12 months).
REVIVE LAB UAE supplies tesamorelin in two vial sizes that map cleanly to standard research-context dosing. Reconstitute with bacteriostatic water (BAC water), injecting diluent slowly down the glass wall of the vial — never directly onto the lyophilized cake, which can mechanically shear peptide secondary structure and reduce bioactivity. Swirl gently; do not vortex.
| Vial Size | BAC Water Added | Concentration | Volume per 1 mg dose | Volume per 2 mg dose | Reconstituted Stability |
|---|---|---|---|---|---|
| Tesamorelin 5 mg | 1 mL | 5 mg/mL | 0.20 mL | 0.40 mL | ~14 days at 2–8°C |
| Tesamorelin 5 mg | 2 mL | 2.5 mg/mL | 0.40 mL | 0.80 mL | ~14 days at 2–8°C |
| Tesamorelin 10 mg | 2 mL | 5 mg/mL | 0.20 mL | 0.40 mL | ~14 days at 2–8°C |
| Tesamorelin 10 mg | 4 mL | 2.5 mg/mL | 0.40 mL | 0.80 mL | ~14 days at 2–8°C |
For a 2 mg/day research-context protocol, a single REVIVE LAB UAE 10 mg vial reconstituted in 2 mL (5 mg/mL concentration) delivers exactly five daily doses at 0.40 mL each — a low-waste, high-precision calculation. Keep reconstituted vials refrigerated at 2–8°C and protected from light. Never freeze a reconstituted vial; ice crystal formation disrupts peptide tertiary structure irreversibly.
Never use a needle wider than 27G for SC peptide protocols. Larger bore needles increase local trauma, raise the risk of inadvertent IM penetration at thin-tissue sites, and introduce absorption variability that undermines quantitative protocols.
A formal rotation schedule is the primary method tool for preventing lipohypertrophy and keeping absorption kinetics stable across a multi-month tesamorelin research protocol. The schedule below distributes seven daily injections across anatomically distinct SC zones, with the deltoid sites anchoring days 1 and 3:
| Day | Site | Landmark Notes |
|---|---|---|
| Day 1 | Left deltoid (lateral upper arm) | 2-3 finger-widths below acromion, lateral surface |
| Day 2 | Right abdomen — upper quadrant | 2 cm lateral to navel, above midline |
| Day 3 | Right deltoid (lateral upper arm) | Mirror of Day 1 on opposite arm |
| Day 4 | Left abdomen — upper quadrant | 2 cm lateral to navel, above midline |
| Day 5 | Left abdomen — lower quadrant | 3–4 cm below navel, lateral |
| Day 6 | Right thigh — lateral mid-third | SC fat overlying vastus lateralis |
| Day 7 | Right abdomen — lower quadrant | 3–4 cm below navel, lateral |
Repeat weekly. For protocols running beyond four weeks, shift the deltoid injection point slightly superior or inferior on alternating weeks — dividing the 4×4 cm target square into four 2×2 cm quadrants and cycling through them adds four additional discrete sub-sites per arm before any zone is reused.
The deltoid carries one practical methodological advantage in VAT-focused tesamorelin protocols: the injection field does not overlap with standard abdominal CT or DEXA scan measurement zones. Investigators quantifying VAT response using cross-sectional imaging at L4–L5 benefit from moving a portion of weekly doses to the deltoid, since repeated abdominal injection can create focal subcutaneous changes that introduce noise into adipose tissue measurement at the primary endpoint anatomical plane.
Lipohypertrophy — localised accumulation of SC fat at chronically injected sites — is the most consistently documented site complication in extended peptide and insulin analog research protocols. In insulin research, investigators coined the term "lipohypertrophy-associated pharmacokinetic variability" (LAPV) to capture what happens to absorption when a single SC zone is overused: the architecture of the SC fat changes, vascularization shifts, and the depot kinetics diverge from the baseline characterization. For tesamorelin, which operates through a timed-release pulsatile mechanism upstream of GH, pharmacokinetic variability at the injection site translates directly into outcome noise.
The Falutz 2007 trial ran 26 weeks with primarily abdominal administration. The subsequent extension — Falutz 2010 — added another 26 weeks in the same cohort. Investigators using tesamorelin on comparable timelines in UAE research contexts are operating in territory where site rotation is not optional; it is the mechanism that keeps the data interpretable. The 7-day schedule above, combined with within-zone sub-site rotation after week four, distributes the injection load across 11–12 distinct tissue locations before any single point is revisited. That is the structural basis for tissue integrity across a 12-month protocol of the type Stanley et al. 2019 conducted in the Lancet HIV cohort.
Investigators across Dubai, Abu Dhabi, Sharjah, and beyond can buy tesamorelin UAE directly from REVIVE LAB UAE — the peptides UAE supplier that maintains tesamorelin 5 mg and 10 mg in cold storage in Dubai and dispatches every order with validated cold-chain packaging. REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates — same-day in Dubai, next-day everywhere else. Cash on delivery is standard. Lot-specific HPLC purity documentation (target ≥99%) is available on request for every batch.
Grey-market tesamorelin supply in the Gulf frequently arrives without documented storage history — a critical failure point for a temperature-sensitive GHRH analog. A supplier who cannot provide a cold-chain custody record and a lot-specific COA is not a research-grade source, regardless of price. REVIVE LAB UAE was built specifically to close that gap for peptides UAE investigators.
| Emirate / City | Delivery Window | Cash on Delivery | Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm Jumeirah, Jumeirah, Emirates Hills) | Same-day, 4–8 hours | Yes | Discreet, unbranded |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem, Al Ain) | Next-day, 18–24 hours | Yes | Discreet, unbranded |
| Sharjah / Ajman | Same-day or next-day, 8–18 hours | Yes | Discreet, unbranded |
| Ras Al Khaimah / Fujairah / Umm Al Quwain | Next-day, 18–24 hours | Yes | Discreet, unbranded |
A Dubai Marina researcher who orders tesamorelin Dubai before 2 pm typically has cold-pack vials in hand by evening. For Abu Dhabi Corniche, Yas Island, and Saadiyat, orders placed the same day dispatch immediately and arrive by the following morning. Tesamorelin Dubai 24h delivery is not a marketing line — it is a function of REVIVE LAB UAE maintaining genuine in-emirate cold storage and a dedicated courier network, not relying on third-party freight.
REVIVE LAB UAE stocks tesamorelin 5 mg and 10 mg vials, HPLC-verified with lot-level COA, cold-chain dispatched to all seven UAE emirates. Investigators in Dubai receive same-day delivery (4–8 hours); researchers in Abu Dhabi, Sharjah, RAK, Fujairah, Ajman, and Umm Al Quwain receive vials within 24 hours. Cash on delivery is supported throughout the UAE. All shipments use plain, unbranded outer cartons by default.
REVIVE LAB UAE stocks tesamorelin 5 mg and 10 mg vials only — the two strengths validated across the Falutz 2007, Falutz 2010, Stanley 2014, and Stanley 2019 trial series. Both sizes are available for same-day dispatch in Dubai and 24-hour delivery across all UAE emirates. Lot-level COA and HPLC purity certificates are available on request for every batch.
Yes. REVIVE LAB UAE supports cash on delivery across all seven emirates: Dubai (same-day, 4–8 hours), Abu Dhabi (next-day, 18–24 hours), Sharjah, Ajman, Ras Al Khaimah, Fujairah, and Umm Al Quwain. All shipments default to plain, unbranded outer cartons — discreet packaging at no extra charge. Tesamorelin same day Dubai orders placed before the daily cut-off are dispatched on the same business day.